Voutsadakis Ioannis A
Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, Ontario, Canada, and Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Cent European J Urol. 2020;73(4):476-481. doi: 10.5173/ceju.2020.0176. Epub 2020 Nov 20.
Urachal adenocarcinoma is a rare cancer and is treated based on the experience from case series and expert opinion as no randomized studies have been performed. This report adds to the current literature the experience of a patient with locally advanced urachal adenocarcinoma who was treated with combination of neoadjuvant gemcitabine/ cisplatin chemotherapy, surgery and adjuvant chemotherapy and has obtained a long recurrence free survival currently for more than 5 years. Although 5-FU-based chemotherapy is favored by many experts in the treatment of metastatic urachal adenocarcinoma, gemcitabine-based regimens have produced partial responses in metastatic disease and have been used in peri-operative treatment with a manageable adverse effect profile. A brief discussion of molecular lesions in urachal carcinomas and of the emerging role of targeted therapies is included in the current report.
脐尿管腺癌是一种罕见的癌症，由于尚未进行随机研究，目前其治疗是基于病例系列经验和专家意见。本报告为当前文献增添了一名局部晚期脐尿管腺癌患者的治疗经验，该患者接受了吉西他滨/顺铂新辅助化疗、手术及辅助化疗联合治疗，目前已获得超过5年的长期无复发生存期。尽管在转移性脐尿管腺癌的治疗中，许多专家更倾向于使用基于5-氟尿嘧啶的化疗，但基于吉西他滨的方案在转移性疾病中产生了部分缓解，且已用于围手术期治疗，不良反应可控。本报告还简要讨论了脐尿管癌的分子病变以及靶向治疗的新兴作用。
